Clinical Trials Logo

Clinical Trial Summary

This study aims to assess anxiety/depression and life quality of patients included in clinical trials versus patients treated in a standard way.


Clinical Trial Description

This study aims to assess anxiety/depression and life quality of patients included in clinical trials versus patients treated in a standard way A case-control study ;


Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT01606033
Study type Interventional
Source Centre Oscar Lambret
Contact
Status Completed
Phase N/A
Start date March 2011
Completion date February 2014

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02226289 - Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment Phase 2
Terminated NCT02566421 - Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery N/A
Active, not recruiting NCT04418661 - Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies Phase 1/Phase 2
Completed NCT00525057 - Dalteparin in Preventing DVT in Participants With Cancer N/A
Terminated NCT03871348 - A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02775292 - Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 Phase 1
Recruiting NCT05617716 - Spine Radiosurgery for Symptomatic Metastatic Neoplasms Phase 2
Recruiting NCT05103358 - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) Phase 2
Recruiting NCT02560311 - Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis N/A
Completed NCT02492711 - Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Phase 3